| Abstrakt: |
TROPHIES is a 24-month, prospective, non-comparative, observational study in adult patients with T2D initiating their first injectable glucose-lowering treatment with once-weekly dulaglutide (DU) or once-daily liraglutide (LIRA) in France, Germany, and Italy. Patient disposition, clinical characteristics, and GLP-1 RA persistence at 12-months are described for 1112 DU and 1039 LIRA patients eligible for analysis. The 12-month mean HbA1c (SD) change from baseline was -1.2 (1.4)% (baseline, 8.2 (1.2)%) in the DU cohort and -1.2 (1.5)% (baseline, 8.3 (1.3)%) in the LIRA cohort. At 12-months, 35% DU and 29% LIRA patients reached their individualized HbA1c target set by the physician at baseline. The mean weight change for DU and LIRA from baseline to 12-months was -3.3 (5.5) kg and -3.4 (6.1) kg, respectively. Probability (95%CI) of GLP-1 RA persistence was high in both DU and LIRA cohorts at 12-months: DU, 0.88 (0.86-0.90); LIRA 0.82 (0.79-0.84); (Figure). In summary, these data show similar HbA1c and weight reductions for DU and LIRA at 12-months with good persistence, consistent with known clinical trial results. Disclosure: B. Guerci: Advisory Panel; Self; Abbott, Novartis Pharmaceuticals Corporation, Board Member; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Lilly Diabetes, Novo Nordisk, Sanofi, Consultant; Self; AstraZeneca, Intercept Pharmaceuticals, Inc. M. O. Orsini federici: Employee; Self; Eli Lilly and Company. F. Giorgino: Consultant; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Lilly Diabetes, Novo Nordisk, Roche Diabetes Care, Sanofi, Research Support; Self; Lilly Diabetes, Roche Diabetes Care. L. Garcia: Employee; Self; Eli Lilly and Company. K. Boye: Employee; Self; Eli Lilly and Company, Employee; Spouse/Partner; Eli Lilly and Company. K. Norrbacka: Employee; Self; Oy Eli Lilly Finland Ab, Stock/Shareholder; Self; Eli Lilly and Company. H. Sapin: Employee; Self; Eli Lilly and Company. E. Heitmann: Employee; Self; Lilly Diabetes. J. Lebrec: Consultant; Self; Eli Lilly and Company. A. Dib: Advisory Panel; Spouse/Partner; Boehringer Ingelheim Pharmaceuticals, Inc., Employee; Self; Eli Lilly and Company, Stock/Shareholder; Self; Eli Lilly and Company. [ABSTRACT FROM AUTHOR] |
